GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL

Gemcitabine Clinical Trial

Official title:

GDPE/CEOPE Compared With CEOPE as the First-line Therapy for Newly Diagnosed Patients With Peripheral T-Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03884205
• Other study ID #: Gemcitabine-PTCL
• Status: Recruiting
• Start date: April 1, 2019
• Est. completion date: September 30, 2020

Study information

• Verified date: March 2019
• Source: Shandong Provincial Hospital
• Contact: Yujie MS JIANG, Dr
• Phone: 8613370506886
• Email: yujiejiang05[@]126.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. There is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by National Comprehensive Cancer Network (NCCN) for those patients. Former studies confirmed that GDP (Gemcitabine, Dexamethasone, and Cis-platinum) is superior with CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisone). Combination with etoposide can improve the outcome of some patients with high risk factors. The aim of our study is to compare the response and survival rate of GDPE/CEOPE (gemcitabine, cis-platinum, etoposide, and dexamethasone/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone) with those of CEOPE regimen, looking forward to its superiority in efficacy and safety for the newly diagnosed adult patients with PTCL.

Description:

Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. Five-year PFS (progression-free survival) and OS (overall survival) for these patients received classic CHOP regimen is less than 30%. High-dose intensive chemotherapy doesn't demonstrate better response. At present, there is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by NCCN for those patients.

For the less efficacy of CHOP or CHOP-like regimen, multi-drug combination strategy has been the therapy tendency in PTCL. Zhang et al, reported that GDP compared with CHOP as the therapy strategy for PTCL-NOS (Not Otherwise Specified). The response rate was 78.57% in GDP group and 60.00% in CHOP group, respectively. DFS (disease-free survival) was 9.79 and 4.2 months in above two groups. They concluded that GDP is superior to CHOP. The main side-effect of two regimens is hematological toxicity. Combination with etoposide can improve the outcome of some patients with high risk factors. Furthermore, high-dose combined with ASCT (autologous stem cell transplantation) has been the first-line therapy for PTCL. Some refractory/relapsed patients with PTCL will benefit from allogeneic bone marrow transplantation. However, about 30% patients with PTCL have no chance to receive ASCT for multiple reasons. So, it is urgent to explore new combination-therapy regimen to improve the outcome for patients with PTCL.

The aim of our study is to compare the response and survival rate of GDPE/CEOPE (gemcitabine, cis-platinum, etoposide, and dexamethasone/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone) with those of CEOPE (/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone ) regimen, looking forward to its superiority in efficacy and safety for the newly diagnosed adult patients with PTCL.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 30, 2020
• Est. primary completion date: March 31, 2020
• Gender: All
• Age group: 16 Years to 75 Years

Eligibility

Inclusion Criteria:

• Peripheral T Cell Lymphoma, Not Otherwise Specified

• Angioimmunoblastic T Cell Lymphoma

• ALK-negative Anaplastic Large Cell Lymphoma

• Enteropathy Associated T Cell Lymphoma

• Subcutaneous Panniculitis Like T Cell Lymphoma

• Acute T-cell Leukemia/Lymphoma

Exclusion Criteria:

• woman in pregnancy or lactation

• allergic to any intervention drug

• unsuitable to the study due to severe complication

• enrolled to other study during the past 6 months

• NK/T lymphoma ALK-positive Anaplastic Large Cell Lymphoma

Related Conditions & MeSH terms

• Gemcitabine
• PTCL

Locations

Country	Name	City	State
China	Yujie MS JIANG	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RR	Response Rate (including complete response & partial response)	1 year
Secondary	PFS	progression free survival	1 year